Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05110742 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
A Phase 1 study of Hematological Malignancy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT05110742 is a Phase 1 study of Hematological Malignancy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 64 participants, below the 114-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05110742, a Phase 1 study of Hematological Malignancy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia. The efficacy and optimal dose will be identified for individual diseases.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine Phosphate
- DRUG CAR.5/IL15-transduced CB-NK cells
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05110742
The ClinicalTrials.gov registry entry for NCT05110742 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 114-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (44% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematological Malignancy appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT05110742 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05110742 about?
NCT05110742 is a clinical study titled "Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances". To determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia. The efficacy and optimal dose will be identified for individual diseases.
What is the current status of trial NCT05110742?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2024-04-22. Estimated completion is 2027-12-30.
What conditions does trial NCT05110742 study?
This clinical trial studies the following conditions: Hematological Malignancy.
What interventions are being tested in trial NCT05110742?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine Phosphate (DRUG), CAR.5/IL15-transduced CB-NK cells (DRUG).
Who is sponsoring clinical trial NCT05110742?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05110742 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
COMPLETED · Phase 1
-
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
COMPLETED · Phase 1
-
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
RECRUITING · Phase 2
-
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
RECRUITING · Phase 2
-
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
RECRUITING
-
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.